Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating restated by analysts at Cantor Fitzgerald in a research note issued to investors on Friday. They currently have a $21.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 13.21% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Maxim Group set a $17.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 29th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research note on Thursday, August 24th. BidaskClub downgraded shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Tuesday, July 11th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $22.00 target price on shares of Abeona Therapeutics in a research note on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $18.50.

Shares of Abeona Therapeutics (NASDAQ ABEO) traded down 4.54% during mid-day trading on Friday, reaching $17.66. The company’s stock had a trading volume of 802,944 shares. Abeona Therapeutics has a 52 week low of $4.05 and a 52 week high of $18.90. The company’s 50-day moving average is $13.68 and its 200-day moving average is $8.15. The stock’s market capitalization is $711.47 million.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million. Equities analysts predict that Abeona Therapeutics will post ($0.68) EPS for the current year.

WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/06/abeona-therapeutics-inc-abeo-earns-buy-rating-from-cantor-fitzgerald.html.

Large investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board acquired a new stake in Abeona Therapeutics in the second quarter valued at about $122,000. Family Management Corp acquired a new stake in Abeona Therapeutics in the first quarter valued at about $120,000. Rhumbline Advisers acquired a new stake in Abeona Therapeutics in the second quarter valued at about $190,000. Schwab Charles Investment Management Inc. acquired a new stake in Abeona Therapeutics in the second quarter valued at about $264,000. Finally, Bank of New York Mellon Corp lifted its position in Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 23,358 shares during the period. Hedge funds and other institutional investors own 38.38% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.